摘要
Abstract
Objective To study the clinical effect of sacubitril valsartan sodium tablets(LCZ696)combined with empagliflozin in the treatment of chronic obstructive pulmonary disease(COPD)and chronic heart failure(CHF).Methods A total of 68 patients with COPD and CHF admitted to the Department of Cardiology,Xinfeng County People's Hospital from January to September 2023 were divided into control group(34 patients)and observation group(34 patients)by using the random number table method.Both groups were given basic treatment.On this basis,the control group was treated with LCZ696,while the observation group was treated with LCZ696 combined with empagliflozin.The clinical efficacy,cardiopulmonary function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),forced expiratory volume in one second(FEV1),FEV1/forced vital capacity(FVC)]and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.06%,which was higher than 82.35%of the control group(P＜0.05).After treatment,LVEF,FEV1,FEV1/FVC increased and LVEDD decreased in the two groups.Compared with the control group,LVEF,FEV1,FEV1/FVC were higher and LVEDD was lower in the observation group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group(8.82%)and the control group(5.88%)(P＞0.05).Conclusion LCZ696 combined with empagliflozin is effective in the treatment of COPD and CHF,which can improve the clinical treatment efficiency,improve the cardiopulmonary function of patients,and the safety of medication is good.关键词
慢性阻塞性肺疾病/慢性心力衰竭/沙库巴曲缬沙坦钠片/恩格列净/心肺功能Key words
Chronic obstructive pulmonary disease/Chronic heart failure/Sacubitril valsartan sodium tablets/Engliflozin/Cardiopulmonary function分类
药学
